Gorlin
syndrome, also known as basal cell nevus syndrome, is an inherited
genetic disorder characterized by multiple basal cell skin cancer. The common
symptoms observed during Gorlin syndrome are calcium deposition in brain, jaw
cysts, skeletal changes and developmental disability. The person with Gorlin
syndrome appears with a prominent forehead, widely spaced eyes, small skin
bumps and skin cysts.
Gorlin syndrome is screened by neurological evaluation,
dental X-Ray and measurement of head size. The main treatment for Gorlin
syndrome includes imiquimod cream, chemotherapy, photodynamic therapy and
retinoids. Ascend Biopharmaceuticals Ltd. is in the process of developing ASN-002,
a chemoimmunotherapy, for the treatment of Gorlin syndrome. PellePharm Inc.,
and F. Hoffmann-La Roche Ltd. are some other key players having drugs for
Gorlin syndrome in their pipeline.
Request to Get the Sample Pages at:
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
No comments:
Post a Comment